Equity
€18,600 from €90,863 in 2019
Equity fell by 80% in 6 years.
EPISTATES
Lifetime
9 annual accounts with figures on one time axispeak €224,596 (2022)
€186,136▲ 22.1%
peak €110,066 (2022)
€46,777▲ 21.3%
peak €90,863 (2019)
€18,600unchanged
€1.2m▲ 17.4%
Board1 name since 2016
1 director
Documentsfilings and deeds
16-04-2026106 days before the deadline
2025micro format
Gross margin from €152,499 to €186,136Dividend €46,777Debts from €1.0m to €1.2mInvestments €223,054Cash from €70,182 to €105,315
Key points
from the 2025 annual accountsTurnover
≈ €310,000 estimated
The micro format states no turnover.
Debts
€1.2m 98% of the balance sheet
Financial debts 71%Suppliers 1%Taxes and wages 1%Other 27%
Of this, €344,456 falls due within a year.
Investments
€223,054 2.6 × depreciation
Green is investment, beige is depreciation. Land and buildings stand 15.1% higher than in 2024.
Filings
9 annual accounts 1 late
The 2017 accounts came 9 days late. The other eight were filed on time.
Position in the sector
1.5%
Lower solvency than 90% of companies in head offices and management consultancy. Sector median 55.5% · 41,240 companies.
Checked score
Bankruptcy probability within 12 months
Financial strength
Score breakdown
Comparable companies, two years later
In July 2024, 1,448 companies had the same profile as EPISTATES has now. Each dot stands for 4 companies, two years later.
95.6%
were still trading
2.1%
stopped another way
2.0%
went bankrupt
Another 0.3% stopped without a precise date, possibly only after those two years.
Test of the method
The method was tested on the 497,762 companies of July 2024. Each company was given the bankruptcy share of the same profile a year earlier, in July 2023. The expectation was that 1.6% would go bankrupt within 24 months. In fact 1.7% went bankrupt.
| Group | Expected | Actual |
|---|---|---|
| 1 | 0.2% | 0.2% |
| 2 | 0.3% | 0.5% |
| 3 | 0.5% | 0.6% |
| 4 | 0.7% | 0.8% |
| 5 | 0.9% | 0.9% |
| 6 | 1.3% | 1.5% |
| 7 | 1.6% | 1.8% |
| 8 | 1.8% | 1.8% |
| 9 | 2.9% | 3.1% |
| 10 | 5.6% | 6.1% |
A company that went bankrupt had a higher expected share than one that kept going in 74.5% of comparisons. The level depends on the economy. In a year with more bankruptcies than the year before, the actual share is higher than the expected one.
This is an observation about 1,448 companies, not a prediction for EPISTATES. The sector does not count, because the KBO no longer lists a sector for a company that has stopped. By sector, mostly the survivors would count, which would paint too rosy a picture.
Credit verdict
Credit check for an amount and term of your choice
Show the recommended maximum and see how the verdict changes with amount, term and advance.
The scores and ratios are Checked's own calculations, not a credit decision.
Signals
Recent changes
Registered in the Peppol Directory
Reachable for e-invoices through 0208:0661823080
Change of role: , from manager to director
Permanent representative: · Director discharge: · General meeting of 15-07-2022 · Gazette deed
Registered office moved within Braine-l'Alleud
New registered office: rue Baty Gigot 69, 1420 Braine l'Alleud · Previous registered office: rue Baty Gigot 242, 1420 Braine l'Alleud · Gazette deed
Incorporation
Founding capital of €18,600, 100 shares · Founder: · Appointment: (manager and permanent representative) · published on 01-09-2016 · Gazette deed
Comparable companies
same main activity, similar in size and age| Company | ||||
|---|---|---|---|---|
| EPISTATES Braine-l'Alleud | €1.2m | €186,136 | 1.5% | - |
| INNOV4U Rixensart | €1.3m | €198,182 | 53.2% | - |
| AMC MANAGEMENT Incourt | €1.3m | €224,903 | 64.4% | - |
| Brevi Brakel | €1.1m | €193,245 | 16.2% | 0 |
| RDS CONSULT Châtelet | €1.2m | €179,768 | -1.4% | - |
| M-CONSULT & DEV. Estaimpuis | €1.2m | €202,021 | 29.3% | - |
| Van Hulst Wim Brasschaat | €1.1m | €174,115 | 63.6% | - |
These companies have the same main activity as EPISTATES: business and other management consultancy (NACE 70200). They are comparable in size and age: total assets between €1.1m and €1.3m, founded between 2016 and 2017.
Official details
Source: KBO- Status
- Active since 30-08-2016Normal situation
- Activity
- Business and other management consultancyNACE 70200and 2 others
- Establishment unit
- 2.256.137.7471420 Braine-l'Alleud, since 30-08-2016
- Financial year end
- 31 December
- Peppol
- Reachable since 12-12-2025
Annual accounts 2025
- €1.2m▲ 17.1%
- Filing
- Filed on 16-04-2026, 106 days before the end of the filing period
Insights on EPISTATES
EPISTATES files the micro format. That format states no turnover. The gross margin rose from €100,238 in 2017 to €186,136 in 2025.
The balance sheet grew most from 2018 to 2019 through fixed assets, financed with long-term debt.
Sources: KBO register, filings at the National Bank, Belgian Official Gazette. Click a figure with a dotted line for the item and the filing.
Key facts about EPISTATES
- What is the company number of EPISTATES?
- The company number of EPISTATES is 0661.823.080. The VAT number is the same number with BE in front: BE 0661.823.080.
- Where is EPISTATES based?
- The registered office is at Rue Baty Gigot 69, 1420 Braine-l'Alleud.Company details
- What does EPISTATES do?
- According to the KBO register, the main activity is business and other management consultancy (NACE 70200).
- What is the legal form of EPISTATES?
- EPISTATES is a private limited company (BV).
- When was EPISTATES founded?
- EPISTATES was founded on 30-08-2016.
- Is EPISTATES still active?
- Yes, EPISTATES is an active enterprise in the KBO register.
- What is the turnover of EPISTATES?
- The turnover in financial year 2025 is ≈ €310,000. This figure is estimated from the gross margin of €186,136 and 122 comparable companies (NACE 70200). It probably lies between €260,000 and €370,000.Financials
- Is EPISTATES profitable?
- In financial year 2025, EPISTATES made a profit of €46,777.
- Where can I find the annual accounts of EPISTATES?
- EPISTATES filed 9 annual accounts with the National Bank of Belgium, the latest for financial year 2025.
- When are the next annual accounts of EPISTATES due?
- EPISTATES must file the annual accounts for financial year 2026 by 31-07-2027.Timeline
Next steps
Work out how much credit to give this customer and on what payment terms.Credit check Check what to know before you do business with this company.Supplier due diligence Check whether you can accept this company as a client under the anti-money-laundering law.AML client file Check which of your other customers you can e-invoice via Peppol.Peppol check Compare this company with its sector.Sector benchmark See what changed in the latest annual accounts.What changed
See how customers, suppliers and banks see your own company and what to improve first.